| # | Title | Journal | Year | Citations |
|---|
| 1 | Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas | JAMA Oncology | 2022 | 107 |
| 2 | Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer | JAMA - Journal of the American Medical Association | 2021 | 63 |
| 3 | CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer | Journal of Clinical Oncology | 2022 | 62 |
| 4 | Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216) | JAMA Oncology | 2022 | 32 |
| 5 | Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia | Blood Advances | 2021 | 28 |
| 6 | Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations | Journal of Clinical Oncology | 2023 | 27 |
| 7 | Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer | JAMA Oncology | 2020 | 24 |
| 8 | Association of Long-term Outcomes With Stereotactic Radiosurgery vs Whole-Brain Radiotherapy for Resected Brain Metastasis | JAMA Oncology | 2022 | 24 |
| 9 | Impact of the COVID-19 Pandemic on Cancer Clinical Trials | Annals of Surgical Oncology | 2021 | 23 |
| 10 | Diet- and Lifestyle‐Based Prediction Models to Estimate Cancer Recurrence and Death in Patients With Stage III Colon Cancer (CALGB 89803/Alliance) | Journal of Clinical Oncology | 2022 | 20 |
| 11 | Phase II Study of Enzalutamide for Patients With Androgen Receptor–Positive Salivary Gland Cancers (Alliance A091404) | Journal of Clinical Oncology | 2022 | 20 |
| 12 | Acquired Genomic Alterations on First-Line Chemotherapy With Cetuximab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of the CALGB/SWOG-80405 Trial (Alliance) | Journal of Clinical Oncology | 2023 | 17 |
| 13 | Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance) | Clinical Cancer Research | 2021 | 13 |
| 14 | Physical Activity in Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance) | Journal of Clinical Oncology | 2023 | 11 |
| 15 | Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer | JAMA Oncology | 2023 | 11 |
| 16 | Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer | Clinical Lung Cancer | 2022 | 10 |
| 17 | Inequities in Alliance Acute Leukemia Clinical Trial and Biobank Participation: Defining Targets for Intervention | Journal of Clinical Oncology | 2022 | 9 |
| 18 | ARID1A mutations confer intrinsic and acquired resistance to cetuximab treatment in colorectal cancer | Nature Communications | 2022 | 9 |
| 19 | Positron Emission Tomography–Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance) | Journal of Clinical Oncology | 2023 | 9 |
| 20 | Association of Diet Quality With Survival Among People With Metastatic Colorectal Cancer in the Cancer and Leukemia B and Southwest Oncology Group 80405 Trial | JAMA Network Open | 2020 | 8 |
| 21 | Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer | JAMA Oncology | 2023 | 8 |
| 22 | Tumor Immunogenomic Features Determine Outcomes in Patients with Metastatic Colorectal Cancer Treated with Standard-of-Care Combinations of Bevacizumab and Cetuximab | Clinical Cancer Research | 2022 | 7 |
| 23 | IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405 | JNCI Cancer Spectrum | 2021 | 6 |
| 24 | Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance) | Breast Cancer Research and Treatment | 2021 | 5 |
| 25 | Marital Status, Living Arrangement, and Cancer Recurrence and Survival in Patients with Stage III Colon Cancer: Findings from CALGB 89803 (Alliance) | Oncologist | 2022 | 5 |
| 26 | Race, Income, and Survival in Stage III Colon Cancer: CALGB 89803 (Alliance) | JNCI Cancer Spectrum | 2021 | 4 |
| 27 | Circulating tumor DNA dynamics on front-line chemotherapy with bevacizumab or cetuximab in metastatic colorectal cancer: A biomarker analysis for acquired genomic alterations in CALGB/SWOG 80405 (Alliance) randomized trial. | Journal of Clinical Oncology | 2022 | 4 |
| 28 | ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA | European Journal of Cancer | 2022 | 4 |
| 29 | Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial) | Journal of Clinical Oncology | 2023 | 4 |
| 30 | Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance). | Journal of Clinical Oncology | 2020 | 3 |
| 31 | Age and comorbidity association with survival outcomes in metastatic colorectal cancer: CALGB 80405 analysis | Journal of Geriatric Oncology | 2022 | 3 |
| 32 | Associations Between Unprocessed Red Meat and Processed Meat With Risk of Recurrence and Mortality in Patients With Stage III Colon Cancer | JAMA Network Open | 2022 | 3 |
| 33 | Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702 | Journal of Clinical Oncology | 2023 | 3 |
| 34 | Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance) | Neuro-Oncology Advances | 2022 | 2 |
| 35 | KDR genetic predictor of toxicities induced by sorafenib and regorafenib | Pharmacogenomics Journal | 2022 | 2 |
| 36 | Association of circulating markers with cognitive decline after radiation therapy for brain metastasis | Neuro-Oncology | 2023 | 2 |
| 37 | Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer | Annals of Surgical Oncology | 2023 | 2 |
| 38 | Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men’s Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]) | European Urology Focus | 2022 | 1 |
| 39 | A phase II single-arm study of the FGFR inhibitor pemigatinib in patients with metastatic colorectal cancer (mCRC) harboring FGF/FGFR alterations. | Journal of Clinical Oncology | 2023 | 1 |
| 40 | Phase Ib open-label study to evaluate safety, tolerability, immunogenicity, and efficacy of multiple subcutaneous injections of PolyPEPI1018 vaccine as an add-on immunotherapy to TAS-102 in participants with late-stage microsatellite-stable metastatic colorectal cancer (MSS mCRC; OBERTO-201). | Journal of Clinical Oncology | 2023 | 1 |
| 41 | Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma. | Journal of Clinical Oncology | 2023 | 1 |
| 42 | Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC). | Journal of Clinical Oncology | 2022 | 0 |
| 43 | P968: ADDITION OF IXAZOMIB TO POMALIDOMIDE AND DEXAMETHASONE IMPROVES PROGRESSION-FREE SURVIVAL FOR MULTIPLE MYELOMA PATIENTS PROGRESSING ON LENALIDOMIDE AS PART OF 1ST LINE THERAPY: ALLIANCE A061202 | HemaSphere | 0 | 0 |
| 44 | Predictive value of MAOB gene expression for targeted therapy in patients (pts) with metastatic colorectal cancer (mCRC) enrolled in CALGB (Alliance)/SWOG 80405. | Journal of Clinical Oncology | 2022 | 0 |
| 45 | Gene expression of vitamin D (VitD) pathway markers and survival in patients (Pts) with metastatic colorectal cancer (mCRC): CALGB/SWOG 80405 (Alliance). | Journal of Clinical Oncology | 2022 | 0 |
| 46 | Analysis of patient (pt) withdrawal of consent using 11,993 pts from 58 alliance for clinical trials in oncology trials. | Journal of Clinical Oncology | 2022 | 0 |
| 47 | Enrollment patterns and site-level predictors of Black participant recruitment to a multisite randomized clinical trial (RCT) of endocrine therapy adherence support. | Journal of Clinical Oncology | 2022 | 0 |
| 48 | Local/Regional Recurrence Rates After Breast-Conserving Therapy in Patients Enrolled in Legacy Trials of the Alliance for Clinical Trials in Oncology (AFT-01) | Annals of Surgery | 2023 | 0 |
| 49 | ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer | Annals of Surgical Oncology | 2023 | 0 |
| 50 | Outcomes of Older Adults With AML Treated in Community Versus Academic Centers: An Analysis of Alliance Trials | JCO Oncology Practice | 0 | 0 |
